tiprankstipranks
Trending News
More News >
Crispr Therapeutics (CRSP)
:CRSP
US Market

Crispr Therapeutics AG (CRSP) Stock Forecast & Price Target

Compare
9,333 Followers
See the Price Targets and Ratings of:

CRSP Analyst Ratings

Moderate Buy
20Ratings
Moderate Buy
14 Buy
6 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Crispr
Therapeutics AG
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CRSP Stock 12 Month Forecast

Average Price Target

$68.65
▲(80.47%Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $68.65 with a high forecast of $105.00 and a low forecast of $35.00. The average price target represents a 80.47% change from the last price of $38.04.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","69":"$69","106":"$106","50.5":"$50.5","87.5":"$87.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68.65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$68.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,50.5,69,87.5,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.95,42.184615384615384,47.41923076923077,52.65384615384616,57.88846153846154,63.12307692307692,68.3576923076923,73.5923076923077,78.82692307692308,84.06153846153846,89.29615384615386,94.53076923076924,99.76538461538462,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.95,39.38846153846154,41.82692307692308,44.26538461538462,46.70384615384616,49.142307692307696,51.580769230769235,54.019230769230774,56.45769230769231,58.89615384615385,61.33461538461539,63.77307692307693,66.21153846153847,{"y":68.65,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.95,36.800000000000004,36.650000000000006,36.5,36.35,36.2,36.050000000000004,35.9,35.75,35.6,35.45,35.3,35.15,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.81,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.74,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.85,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.73,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$105.00Average Price Target$68.65Lowest Price Target$35.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CRSP
TipRanks AITipRanks
Not Ranked
TipRanks
$38
Hold
-0.11%
Downside
Reiterated
06/04/25
The overall stock score for Crispr Therapeutics AG is primarily impacted by its financial performance and valuation challenges. Despite a strong balance sheet, the company faces operational inefficiencies and cash flow issues, leading to a lower financial performance score. Technical analysis provides mixed signals, reflecting neutral to slightly bearish momentum. Valuation concerns further weigh down the score, driven by negative earnings and the lack of a dividend yield. While recent corporate events are promising, they do not influence the score directly due to weight redistribution.
William Blair Analyst forecast on CRSP
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
06/03/25
Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG
Bernstein Analyst forecast on CRSP
Unknown AnalystBernstein
Not Ranked
Bernstein
Hold
Assigned
05/27/25
Bernstein Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)We rate the following companies Market-Perform: ALLO, ARWR, BIIB, CRSP, IONS, VRTX.
Citizens JMP Analyst forecast on CRSP
Silvan TuerkcanCitizens JMP
Citizens JMP
$86
Buy
126.08%
Upside
Reiterated
05/21/25
Citizens JMP reiterates Market Outperform Rating on CRISPR Therapeutics (CRSP)Citizens JMP analyst Silvan Tuerkcan reiterated a Market Outperform rating and $86.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).
Leerink Partners Analyst forecast on CRSP
Mani ForooharLeerink Partners
Leerink Partners
$58$56
Buy
47.21%
Upside
Reiterated
05/21/25
Leerink Partners Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
Truist Financial Analyst forecast on CRSP
Joon LeeTruist Financial
Truist Financial
Buy
Reiterated
05/20/25
Truist Financial Remains a Buy on Crispr Therapeutics AG (CRSP)
Needham Analyst forecast on CRSP
Gil BlumNeedham
Needham
$81
Buy
112.93%
Upside
Reiterated
05/20/25
Strategic Growth and De-risking: Gil Blum's Buy Rating on Crispr Therapeutics AG
Mizuho Securities Analyst forecast on CRSP
Salim SyedMizuho Securities
Mizuho Securities
$99$85
Buy
123.45%
Upside
Reiterated
05/20/25
Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
Piper Sandler Analyst forecast on CRSP
Edward TenthoffPiper Sandler
Piper Sandler
$105
Buy
176.03%
Upside
Reiterated
05/20/25
Piper Sandler Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)
BMO Capital Analyst forecast on CRSP
Kostas BiliourisBMO Capital
BMO Capital
$75
Buy
97.16%
Upside
Reiterated
05/20/25
Promising Potential of Crispr Therapeutics AG: Buy Rating Backed by Strategic Partnership and Diversified Pipeline
H.C. Wainwright Analyst forecast on CRSP
Mitchell KapoorH.C. Wainwright
H.C. Wainwright
$65
Buy
70.87%
Upside
Reiterated
05/20/25
Crispr Therapeutics AG: Strategic Advancements and Growth Potential Drive Buy Rating
Goldman Sachs Analyst forecast on CRSP
Salveen RichterGoldman Sachs
Goldman Sachs
$57$47
Hold
23.55%
Upside
Reiterated
05/19/25
Crispr Therapeutics AG: Promising Partnership with Sirius Therapeutics Amidst Clinical and Market Uncertainties Warrants Hold Rating
Citi
$82
Buy
115.56%
Upside
Reiterated
05/19/25
Strategic Expansion and Promising Ventures Drive Buy Rating for Crispr Therapeutics AG
Bank of America Securities Analyst forecast on CRSP
Alec StranahanBank of America Securities
Bank of America Securities
$79
Buy
107.68%
Upside
Reiterated
05/19/25
Bank of America Securities Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Barclays Analyst forecast on CRSP
Gena WangBarclays
Barclays
$56$42
Hold
10.41%
Upside
Reiterated
05/09/25
Crispr Therapeutics AG (CRSP) Gets a Hold from Barclays
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CRSP
TipRanks AITipRanks
Not Ranked
TipRanks
$38
Hold
-0.11%
Downside
Reiterated
06/04/25
The overall stock score for Crispr Therapeutics AG is primarily impacted by its financial performance and valuation challenges. Despite a strong balance sheet, the company faces operational inefficiencies and cash flow issues, leading to a lower financial performance score. Technical analysis provides mixed signals, reflecting neutral to slightly bearish momentum. Valuation concerns further weigh down the score, driven by negative earnings and the lack of a dividend yield. While recent corporate events are promising, they do not influence the score directly due to weight redistribution.
William Blair Analyst forecast on CRSP
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
06/03/25
Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG
Bernstein Analyst forecast on CRSP
Unknown AnalystBernstein
Not Ranked
Bernstein
Hold
Assigned
05/27/25
Bernstein Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)We rate the following companies Market-Perform: ALLO, ARWR, BIIB, CRSP, IONS, VRTX.
Citizens JMP Analyst forecast on CRSP
Silvan TuerkcanCitizens JMP
Citizens JMP
$86
Buy
126.08%
Upside
Reiterated
05/21/25
Citizens JMP reiterates Market Outperform Rating on CRISPR Therapeutics (CRSP)Citizens JMP analyst Silvan Tuerkcan reiterated a Market Outperform rating and $86.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).
Leerink Partners Analyst forecast on CRSP
Mani ForooharLeerink Partners
Leerink Partners
$58$56
Buy
47.21%
Upside
Reiterated
05/21/25
Leerink Partners Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
Truist Financial Analyst forecast on CRSP
Joon LeeTruist Financial
Truist Financial
Buy
Reiterated
05/20/25
Truist Financial Remains a Buy on Crispr Therapeutics AG (CRSP)
Needham Analyst forecast on CRSP
Gil BlumNeedham
Needham
$81
Buy
112.93%
Upside
Reiterated
05/20/25
Strategic Growth and De-risking: Gil Blum's Buy Rating on Crispr Therapeutics AG
Mizuho Securities Analyst forecast on CRSP
Salim SyedMizuho Securities
Mizuho Securities
$99$85
Buy
123.45%
Upside
Reiterated
05/20/25
Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
Piper Sandler Analyst forecast on CRSP
Edward TenthoffPiper Sandler
Piper Sandler
$105
Buy
176.03%
Upside
Reiterated
05/20/25
Piper Sandler Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)
BMO Capital Analyst forecast on CRSP
Kostas BiliourisBMO Capital
BMO Capital
$75
Buy
97.16%
Upside
Reiterated
05/20/25
Promising Potential of Crispr Therapeutics AG: Buy Rating Backed by Strategic Partnership and Diversified Pipeline
H.C. Wainwright Analyst forecast on CRSP
Mitchell KapoorH.C. Wainwright
H.C. Wainwright
$65
Buy
70.87%
Upside
Reiterated
05/20/25
Crispr Therapeutics AG: Strategic Advancements and Growth Potential Drive Buy Rating
Goldman Sachs Analyst forecast on CRSP
Salveen RichterGoldman Sachs
Goldman Sachs
$57$47
Hold
23.55%
Upside
Reiterated
05/19/25
Crispr Therapeutics AG: Promising Partnership with Sirius Therapeutics Amidst Clinical and Market Uncertainties Warrants Hold Rating
Citi
$82
Buy
115.56%
Upside
Reiterated
05/19/25
Strategic Expansion and Promising Ventures Drive Buy Rating for Crispr Therapeutics AG
Bank of America Securities Analyst forecast on CRSP
Alec StranahanBank of America Securities
Bank of America Securities
$79
Buy
107.68%
Upside
Reiterated
05/19/25
Bank of America Securities Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Barclays Analyst forecast on CRSP
Gena WangBarclays
Barclays
$56$42
Hold
10.41%
Upside
Reiterated
05/09/25
Crispr Therapeutics AG (CRSP) Gets a Hold from Barclays
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crispr Therapeutics AG

1 Month
xxx
Success Rate
12/18 ratings generated profit
67%
Average Return
+9.43%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +9.43% per trade.
3 Months
xxx
Success Rate
11/19 ratings generated profit
58%
Average Return
+2.94%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +2.94% per trade.
1 Year
Geulah LivshitsChardan Capital
Success Rate
18/41 ratings generated profit
44%
Average Return
+17.08%
reiterated a buy rating 29 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 43.90% of your transactions generating a profit, with an average return of +17.08% per trade.
2 Years
xxx
Success Rate
14/41 ratings generated profit
34%
Average Return
+1.93%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 34.15% of your transactions generating a profit, with an average return of +1.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRSP Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
18
16
18
24
23
Buy
5
4
2
5
6
Hold
9
7
8
8
8
Sell
2
2
1
0
0
Strong Sell
0
0
0
0
0
total
34
29
29
37
37
In the current month, CRSP has received 29 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. CRSP average Analyst price target in the past 3 months is 68.65.
Each month's total comprises the sum of three months' worth of ratings.

CRSP Financial Forecast

CRSP Earnings Forecast

Next quarter’s earnings estimate for CRSP is -$1.43 with a range of -$2.27 to -$0.93. The previous quarter’s EPS was -$1.58. CRSP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CRSP has Outperformed its overall industry.
Next quarter’s earnings estimate for CRSP is -$1.43 with a range of -$2.27 to -$0.93. The previous quarter’s EPS was -$1.58. CRSP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CRSP has Outperformed its overall industry.

CRSP Sales Forecast

Next quarter’s sales forecast for CRSP is $5.81M with a range of $0.00 to $31.07M. The previous quarter’s sales results were $865.00K. CRSP beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CRSP has Outperformed its overall industry.
Next quarter’s sales forecast for CRSP is $5.81M with a range of $0.00 to $31.07M. The previous quarter’s sales results were $865.00K. CRSP beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CRSP has Outperformed its overall industry.

CRSP Stock Forecast FAQ

What is CRSP’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics’s 12-month average price target is 68.65.
    What is CRSP’s upside potential, based on the analysts’ average price target?
    Crispr Therapeutics has 80.47% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CRSP a Buy, Sell or Hold?
          Crispr Therapeutics has a consensus rating of Moderate Buy which is based on 14 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Crispr Therapeutics’s price target?
            The average price target for Crispr Therapeutics is 68.65. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $105.00 ,the lowest forecast is $35.00. The average price target represents 80.47% Increase from the current price of $38.04.
              What do analysts say about Crispr Therapeutics?
              Crispr Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of CRSP?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis